BrightSpring Health Services, Inc. research snapshot
BTSG AI stock analysis currently reads BrightSpring Health Services as a fast-growing home and community healthcare platform whose operating momentum is real, but whose stock already prices a large share of that improvement. The company reported Q1 2026 revenue of $3.614 billion, up 25.6% year over year, with Pharmacy Solutions and Provider Services both growing, and raised 2026 revenue guidance to $14.725 billion to $15.225 billion. The analysis is scenario-based rather than a fixed price prediction: the upside case needs durable specialty pharmacy growth, home-health integration, margin expansion, and leverage reduction, while the downside case is tied to reimbursement pressure, sponsor selling, debt, thin GAAP profitability, and a technical failure below recent support.
Current price
$69.53
Market cap
$13.65 billion calculated, $13.65 billion reported reference
AI score
62 / 100
Rating
Strong growth, stretched valuation after a large re-rating
Trend status
Bullish multi-month trend: price is far above the 50-day and 200-day moving averages, but short-term RSI and proximity to the 52-week high raise pullback risk
Data cutoff (updated weekly)
July 12, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | BrightSpring sells complementary pharmacy and provider services for complex senior, specialty, and behavioral populations in lower-cost home and community settings, with recurring medical need rather than discretionary consumer demand. | High |
| Moat | The moat comes from national scale across pharmacy and provider networks, payor and facility relationships, specialized clinical workflows, and density in high-need patient categories. It is weaker than pure software platforms because reimbursement rules, PBM contracts, and labor can be competed away. | Medium |
| Management | CEO Jon Rousseau has pushed specialty pharmacy growth, home-care acquisitions, and leverage reduction, but sponsor secondaries and insider selling keep capital-structure and incentive questions on the table. | Medium |
| Financial trend | FY2025 revenue was $12.911 billion, up 28.2%, with Q1 2026 revenue $3.614 billion, up 25.6%, net income $74 million, and adjusted EBITDA $190 million, while 2026 guidance was raised again. | High |
| Valuation | At $69.53 and about 196.3 million shares, market cap is near $13.65 billion. Trailing PE near 90x on Yahoo TTM EPS of $0.77 looks rich, while forward PE near 40x using about $1.53 to $1.67 EPS estimates still leaves limited margin of safety after the re-rating. | Medium |
| Technical trend | The multi-month trend remains up, with price well above the cited 50-day and 200-day averages, but price is near the 52-week high and several feeds show elevated RSI, so short-term risk of consolidation is high. | Medium-high |
| Risk level | Main risks are Medicaid and Medicare reimbursement cuts, PBM contract pressure, drug pricing and IRA impacts, labor shortages, acquisition integration, leverage, sponsor stock sales, low GAAP margins, and regulatory scrutiny of home health and specialty pharmacy. | High |
| AI confidence | Data confidence is high for reported operating results and medium for forward price paths because the stock already discounts strong growth and technical extremes can reverse quickly. | High data confidence |
| Investment certainty | BTSG is an improving growth platform, but a buy decision still needs evidence that margins and free cash flow can catch up with the stock price, and that support holds after the 2025-2026 re-rating. | Medium-low |
BTSG AI stock forecast
The BTSG AI stock forecast uses scenario math around the $69.53 price reference, forward EPS near $1.53 as a consensus-style base, and a three-year earnings multiple framework. The audited model produced a bearish area near $28, a base area near $65, and a bullish area near $111 before any future capital allocation or share-count effects.
$100 to $115
More likely if 2026 revenue and adjusted EBITDA land near or above the high end of guidance, specialty pharmacy and infusion keep double-digit growth, home-health acquisitions raise Provider margins, leverage falls, and investors sustain a high-30s to low-40s earnings multiple on compounding EPS.
$60 to $72
More likely if revenue grows in the mid-teens, adjusted EBITDA expands but GAAP net margins stay thin, sponsor selling continues in an orderly way, and the market values BTSG near a high-20s to low-30s forward earnings multiple after digesting the 2026 re-rating.
$25 to $35
More likely if reimbursement or PBM pressure hits specialty pharmacy, acquisition integration disappoints, leverage or interest expense reappears as a constraint, guidance is cut, or the multiple compresses toward the high teens on flat EPS.
BTSG AI technical analysis
BTSG AI technical analysis remains constructive on the intermediate trend as of the July 12, 2026 cutoff, but short-term conditions are stretched. Yahoo Finance showed BTSG near $69.53 with a previous close of $68.98, a 52-week range of $19.01 to about $70.72, and strong year-to-date gains. Multiple technical feeds place the 50-day moving average near the low $60s and the 200-day near the low $40s, so the primary trend is still up even if a pause is overdue.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $69.53 | Yahoo Finance intraday reference on July 12, 2026 used as the current price reference for this page. |
| Immediate support | $68.40 to $69.00 | Anchored to the prior close near $68.98 and near-term Barchart-style first support in the upper $68s. |
| Secondary support | $63.00 to $66.50 | Several technical feeds cluster support near the mid-to-high $60s and lower Fibonacci-style zones around $63.50. A break below this zone would weaken the momentum extension. |
| Near resistance | $70.70 to $72.30 | The recent 52-week high area near $70.72 to $72.06 is the first supply zone. A clean break and hold above $72.30 would reopen upside extension. |
| Moving averages | 50-day near $60 to $61, 200-day near $43 to $44 | Chartmill and Financhill style snapshots from early July 2026 showed price far above both intermediate and long-term averages, confirming the primary uptrend. |
| Momentum | RSI recently near 70 to 74 on some feeds | Elevated 14-day RSI readings in early July 2026 suggest overbought short-term conditions even while the intermediate trend stays bullish. |
| Volume and volatility | Recent daily volume often below multi-million average on quiet sessions | Yahoo showed average volume near 3.0 million shares. Pullbacks on rising volume would be more informative than quiet dips under the high. |
| Invalidation | Close below $60.00 | A close below the approximate 50-day moving average area near $60 would invalidate the current extension framework and shift attention to deeper mean reversion toward the mid-$50s or lower. |
BTSG AI trading strategy
The BTSG AI trading strategy below is a rules-based research framework, not personal advice. It links BrightSpring fundamentals, reimbursement news, sponsor selling, leverage updates, and technical confirmation with predefined invalidation levels.
Watch for BTSG to hold above $68.40 and reclaim $72.30 with expanding volume after a pause. Confirmation should include stable 2026 guidance, no major reimbursement shock, and continued Pharmacy and Provider growth.
A failed breakout that slips back below $66.50 after testing highs should reduce setup confidence because it would show supply still dominating near the 52-week high.
If BTSG retests $63.00 to $66.50 without a guidance cut, PBM contract shock, or leverage spike, compare the reaction with healthcare peers, analyst revisions, specialty pharmacy commentary, and free cash flow updates.
Do not treat the pullback as benign if price closes below $60.00 or if management lowers 2026 revenue or adjusted EBITDA guidance.
Track Q2 2026 revenue, Pharmacy versus Provider mix, gross margin, adjusted EBITDA, GAAP net income, free cash flow, leverage ratio, KKR or other sponsor secondary sales, home-health acquisition integration, and any Medicaid or Medicare policy changes.
Position sizing should reflect reimbursement risk, thin GAAP margins, debt, and elevated technical volatility after a multi-bagger re-rating from the 2024-2025 base.
Investment research summary
BrightSpring is paid to deliver pharmacy and provider care for complex patients in home and community settings. Customers and payors fund the company because specialty drugs, infusion, personal care, and home health can be delivered outside higher-cost facilities while still meeting clinical need.
The moat is strongest in national scale, specialized pharmacy operations, payor and facility contracts, clinical staffing density, and the ability to bundle pharmacy with provider services. It is weaker where competitors can bid for the same PBM or Medicaid contracts, or where reimbursement formulas compress gross profit.
The thesis fails if reimbursement or drug pricing reform cuts specialty pharmacy economics, acquisitions fail to integrate, labor costs outrun pricing, leverage reaccelerates, sponsor selling overwhelms demand, or investors decide thin GAAP earnings no longer support a growth multiple.
Management under CEO Jon Rousseau has grown revenue quickly, raised guidance, and reduced leverage on a pro forma basis after the Community Living divestiture and secondary transactions. The open question is whether capital allocation can turn scale into durable free cash flow and less ownership overhang.
The long-term trend favors lower-cost care settings as aging populations, chronic disease, specialty drug utilization, and payor cost pressure push services into the home. The offsets are policy risk, labor shortages, and consolidation among PBMs, payors, and large home-health competitors.
At $69.53, BTSG already reflects a large re-rating from 2025 lows near the high teens to twenties. Margin of safety is limited unless EPS can compound rapidly toward multi-dollar levels while the multiple normalizes without a hard de-rating.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| Current price reference | $69.53 intraday on July 12, 2026, previous close $68.98 | Yahoo Finance BTSG quote | July 12, 2026 |
| Shares outstanding | About 196.3 million shares (Morningstar 196.26M, MarketBeat 197.29M, StockAnalysis current class about 196.59M) | Morningstar, MarketBeat, and StockAnalysis share statistics | July 12, 2026 |
| Market capitalization verification | $13.65 billion calculated from $69.53 x 196.26 million shares, matching the Yahoo reported reference near $13.65 billion | Pineify financial_rigor.py and Yahoo Finance quote snapshot | July 12, 2026 |
| FY2025 revenue | $12.911 billion, up 28.2% from $10.072 billion in 2024 | BrightSpring FY2025 earnings release and Macrotrends | July 12, 2026 |
| FY2025 net income | $104.8 million net income versus a $68.9 million net loss in 2024 | BrightSpring FY2025 earnings release summary | July 12, 2026 |
| FY2025 segment revenue | Pharmacy Solutions about $11.446 billion and Provider Services about $1.465 billion | BrightSpring FY2025 earnings release segment table | July 12, 2026 |
| Q1 2026 revenue and earnings | Revenue $3.614 billion up 25.6%, net income $74 million, adjusted EBITDA $190 million up 44.8% | BrightSpring Q1 2026 earnings release via GlobeNewswire and StockTitan | July 12, 2026 |
| 2026 company guidance | Revenue $14.725 billion to $15.225 billion and adjusted EBITDA $795 million to $825 million after the May 1, 2026 raise | BrightSpring Q1 2026 earnings release | July 12, 2026 |
| TTM revenue and cash | TTM revenue about $13.65 billion, cash about $889 million, debt-to-equity about 136% | Yahoo Finance key statistics snapshot | July 12, 2026 |
| Valuation multiples | Trailing PE near 90x on $0.77 TTM EPS, forward PE near 41x, price-to-sales near 1.1x | Yahoo Finance valuation measures and Pineify financial_rigor.py | July 12, 2026 |
| Technical moving averages | 50-day moving average near $60 to $61 and 200-day near $43 to $44 on early July 2026 technical feeds | Chartmill and Financhill BTSG technical snapshots | July 12, 2026 |
| Analyst target context | Yahoo average target near $66.31 with a high near $90 and BTIG raising a Buy target toward $90 on June 22, 2026 | Yahoo Finance analyst insights | July 12, 2026 |
This BTSG AI stock analysis is an informational research tool only. It is not investment advice, a recommendation, or a guarantee of future performance. Forecast scenarios are based on available public data as of July 12, 2026 and can be wrong if earnings, guidance, reimbursement, regulation, specialty pharmacy economics, leverage, ownership sales, interest rates, or market conditions change.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
